Recently, several reports showed that tumoral indoleamine 2,3-dioxygenase (IDO) expression correlated with a reduced number of CD8+ or CD3+ TILs in colorectal cancer, ovarian cancer, and endometrial cancer, possibly contributing to disease progression and impaired clinical outcome [8–10]. The gene discussed is IDO1; the disease is ovarian carcinoma.